← Book One · The American Healthcare Investigation
Before the Counter
The Hidden Story Behind America's Prescription Drug Prices
Same pill, same factory, same company — a different price at every counter in America. A former VA pharmacy director follows a single prescription backward through manufacturers, hidden middlemen, and a twenty-year-old sentence in federal law, and finds that another arm of the same government pays roughly half as much for the identical drug.
The Investigation
What this book is about
The investigation begins with something almost too ordinary to notice. A woman stands at a pharmacy counter with a small paper bag on the far side of the register. Inside it is the medicine her doctor prescribed a week ago. She can see the pills. What she cannot do is pay for them. So she asks the question pharmacists in every state hear many times a day: is there a cheaper one? Sometimes there is. Often there is not. She leaves with part of the prescription, or none of it, and tells herself she will come back when the timing is better.
That moment repeats thousands of times a day across the country, and it is where Before the Counter, Book One of Robert W. Coleman's documentary trilogy The American Healthcare Investigation, begins. The price on that receipt looks like the simple end of a simple transaction. The book's central claim, argued patiently and with evidence across ten chapters, is that it is not.
Coleman is well positioned to make that claim. He spent more than four decades inside American healthcare as a clinical pharmacist, medical informaticist, researcher, and ultimately Director of Clinical Pharmacy Services at the VA Palo Alto Health Care System. For years he watched the Department of Veterans Affairs buy the same medicines other Americans buy, from the same manufacturers, at dramatically lower prices — not through some secret arrangement, but through an ordinary, disciplined purchasing system hiding in plain sight inside the federal government. That firsthand experience is the investigation's starting point and its method: follow the evidence, wherever it leads, and let the numbers — not outrage — carry the argument.
A Genuine Mystery
The book opens by establishing that a real puzzle exists before attempting to solve it. Imagine two patients, one in Seattle and one in London, each walking out of a doctor's office the same morning with a prescription for the identical brand-name medication — same factory, same manufacturer, same seal on the bottle. One of them may pay two, three, even four times what the other pays. Now narrow the comparison until it can no longer be explained away by geography or national health systems: two American patients, one covered by the Department of Veterans Affairs and one by Medicare, buying the same drug from the same company, and still paying starkly different prices — from the very same federal government.
Coleman frames the scale of that mystery with three numbers, all documented rather than estimated. Roughly three in ten American adults report that in the past year they did not fill a prescription, cut their pills, or skipped doses because they could not afford otherwise — a pattern that touches the insured as much as the uninsured, since high deductibles and copays push people to ration medicine quietly, the same way the uninsured always have. The United States spends roughly two to three times as much per person on prescription drugs as other wealthy nations, not because Americans take more medicine or receive a superior product, but because it is very often the identical product sold abroad, priced differently at the border. And inside the U.S. government itself, the VA pays roughly half of what Medicare pays for the same drugs — a gap later quantified precisely, drawing on a 2020 GAO audit, at about 54 percent less across 399 matched medicines.
Find a gap that size in almost any other industry, Coleman writes, and it would not read as a curiosity. It would read as a lead. He commits the book to four questions that structure everything that follows: What is different? Who made the rules? Who benefits? And who pays the price? The most important clue, he notes early, is already visible — somewhere in American law, the government instructed itself to negotiate hard in one place and forbade itself from negotiating at all in another. That instruction has a date and authors, and the book sets out to find both.
Following the Money
Buy a gallon of paint or a cup of coffee, and everyone involved in the transaction can answer three plain questions afterward: who sold it, who bought it, and what it cost. A prescription refuses to answer any of them. The patient pays one number, the insurer settles on another, the pharmacy is reimbursed a third, and even the manufacturer often nets something different from the price it first announced.
To make sense of that confusion, the book maps the territory before attempting to explain it. A bottle of medicine leaving the manufacturing plant with a single price does not travel in a straight line to the patient. It passes through wholesalers, insurers and the employers who stand behind them, a class of company called a pharmacy benefit manager, the dispensing pharmacy, and often a government program paying part of the bill. At nearly every stop, money changes hands through discounts, fees, and rebates negotiated out of public view. This complexity, Coleman argues, was not designed by anyone on purpose. It accumulated — each new law solving one problem and creating an opening, each new contract answering one question and raising another, with a new participant discovering, again and again, that there was revenue to be earned by standing between the person who needed medicine and the company that made it.
Strip the system to its structure and five parties take a piece of every prescription: the manufacturer, which develops the drug and sets a list price; the wholesaler, which moves it to the pharmacy; the pharmacy itself, which dispenses it for a modest fee; the insurer or self-funded employer, which covers most of the cost; and, in the middle, the pharmacy benefit manager, or PBM — a company most Americans have never heard of despite the fact that one stands behind nearly every prescription filled in the country.
Here the investigation surfaces one of its most striking findings. Three PBMs — CVS Caremark, Express Scripts, and OptumRx — handle roughly eight in ten prescriptions filled in the United States, according to a 2024 FTC staff report. That concentration alone would be notable. What makes it more than a curiosity is what each company is attached to. CVS Caremark sits inside the same corporate family as the insurer Aetna and the CVS pharmacy chain. Express Scripts sits inside Cigna. OptumRx sits inside UnitedHealth Group, alongside the insurer UnitedHealthcare. The company negotiating the price, the company paying the claim, and the company dispensing the drug are, in each case, branches of a single corporate tree. As Coleman puts it, the middleman does not merely stand between buyer and seller — through common ownership, it often is the buyer and the seller.
Importantly, the book resists turning this into a story about villains. Every player — manufacturer, insurer, employer, pharmacy, PBM — is described as responding rationally to the incentives placed in front of it. That refusal to hunt for a single bad actor becomes one of the investigation's organizing principles: a bad incentive produces the same result no matter who occupies the chair, which is exactly what makes the incentive itself worth finding.
The Rebate Illusion
That incentive turns out to live inside one of the least understood arrangements in American healthcare: the drug rebate. In most of the economy, a rebate is money that flows back to the buyer — mail in a card, and a check eventually arrives. In the prescription drug business, the word means something close to the opposite, and Coleman calls this mechanism the keystone of the entire book.
A manufacturer announces a list price of $500 for a new medicine. The PBM negotiates a rebate — say, $200 sent back after the sale — in exchange for favorable placement on the formulary. Everyone at the table announces a win: the manufacturer secured preferred status, the PBM negotiated a large discount, the insurer reduced its costs. One chair at that table was empty. No one represented the patient.
A year later, the list price has risen to $600. The rebate is renegotiated — still a percentage, but now a percentage of a bigger number, so the rebate itself grows along with it. The manufacturer's net take rises. The PBM's rebate rises. And because many insurance plans calculate a patient's coinsurance and deductible spending against the undiscounted list price rather than the negotiated net price, the patient's share rises too — even though the patient never sees a cent of the rebate that grew alongside it. Everyone at the table can walk away with more money. The only person who pays more without receiving anything more is the patient.
This is what economists call a perverse incentive: a rule that rewards people for doing precisely the thing society would rather they didn't. State audits have found spread pricing diverting tens of millions of dollars a year from Medicaid programs, and most states have since banned the practice within Medicaid, though federal action has been more limited.
Coleman is careful to note what this finding does not mean. Rebates are not inherently corrupt, and the book does not argue for abolishing them outright — many employers use rebates to hold down premiums, and some genuinely lower the total cost of care. The problem is structural: a system that rewards a higher starting price is not offering a real discount, no matter what it is called.
The Sentence That Changed Everything
Every investigation reaches a moment when the story turns on one decision. For America's prescription drug system, that moment has a date: 2003, when Congress passed the Medicare Modernization Act, creating the outpatient prescription drug benefit known as Medicare Part D. Two competing designs had been debated. One was direct: let the federal government negotiate prices with manufacturers itself, much as the VA already did. The other trusted competition: let dozens of private insurance plans bargain independently. Coleman presents that second argument fairly, at its strongest, before testing it.
The law that resulted contained a single provision, buried under the bland bureaucratic heading "Noninterference." It states that the Secretary of Health and Human Services may not interfere with negotiations between drug manufacturers and plans, may not require a particular list of covered drugs, and may not institute a price structure for those drugs. Coleman calls it, without exaggeration, the most expensive sentence in U.S. health policy. It effectively told the nation's largest purchaser of prescription drugs, for most of what it buys, that it may not bargain.
More than twenty years later, the record on that experiment is mixed in an instructive way. Medicare Part D succeeded at its central goal — delivering drug coverage to tens of millions of older Americans who had gone without it. But the theory that competition alone would tame prices did not hold, for a reason that connects directly back to the earlier chapters: the private plans doing the negotiating on Medicare's behalf are run by the same pharmacy benefit managers that run commercial insurance, and a negotiator who will not walk away from a brand-name drug a doctor has prescribed is not really negotiating.
Meanwhile, the VA operates under an entirely different statute — Section 8126 of Title 38 of the U.S. Code — that grants it precisely the tools Medicare was denied. The consequence was extraordinary and entirely predictable: the VA pays roughly 54 percent less than Medicare for many of the same drugs. Two federal programs, buying the same medicines from the same companies, operating under opposite instructions, arriving at opposite prices. That gap, Coleman writes, was never an accident.
The wall built in 2003 has since cracked, though only slightly. The Inflation Reduction Act of 2022 carved the first real exception into the noninterference clause, allowing Medicare to negotiate prices for a limited, growing list of high-cost drugs. The first ten negotiated prices took effect January 1, 2026, at discounts ranging from roughly 38 to nearly 80 percent off prior list prices, with fifteen more scheduled for 2027. It is a genuine change — and a narrow one. For the great majority of drugs Medicare buys, the sentence written in 2003 remains the operative law.
America's Hidden Success Story
Having established that the VA is legally permitted to bargain, the book turns to the harder question: how does it actually do it? The answer is not a trick or a single discount. It is a system, built from ordinary discipline rather than any special advantage. Three easy explanations are ruled out at the start: the VA does not receive a secret government-only price, veterans do not receive inferior medicine, and the VA does not simply refuse new treatments.
What it does instead is procure medicine as a single, disciplined national buyer. Rather than letting each of its more than one hundred medical centers shop independently, the VA consolidates the purchasing power of an entire health system into one national order. Beneath that volume sits a legal floor: under Section 8126, manufacturers must sell to the VA at the lower of the Federal Supply Schedule price or the Federal Ceiling Price, fixed by statute at 76 percent of a drug's average non-federal price — a guaranteed discount of at least 24 percent that is not negotiated but simply built into law. On top of that floor, a single national formulary concentrates purchasing volume further, competitive bidding pits similar drugs against each other, and clinical pharmacists sit inside the buying decision itself.
Buying well is only half the discipline; the book calls the second half stewardship — the ethical management of medicines after they are purchased. Coleman draws here on his own published research: at the VA Palo Alto Health Care System, he and colleagues tested prospective review of expensive intravenous antibiotics, examining roughly 1,800 courses of treatment over two years and recommending changes in more than a third of them. Antibiotic costs fell by about a third, with no increase in mortality and no shortening of effective treatment. What began as a local pilot, published in The American Journal of Medicine in 1991, became the basis of a national standard: since 2019, federal rules have required every hospital participating in Medicare or Medicaid to run an antibiotic stewardship program built on the same prospective-review method.
Together, procurement and stewardship compound into a number the book has been building toward since its opening pages. When the Government Accountability Office compared what the VA and Medicare paid for a large sample of the same medicines, it found the VA paid, on average, roughly 54 percent less. A second line of evidence shows its pharmacy cost per patient staying remarkably flat for a decade and a half — about $599 in 1999, about $752 in 2014 — during a period when drug spending nearly everywhere else in the country climbed relentlessly. A third measurement puts a dollar figure on what the country loses by not applying that discipline more broadly: a peer-reviewed study published in JAMA Internal Medicine found that for the set of drugs it examined, Medicare Part D spent about $32.5 billion in a single year where VA pricing would have cost about $18.0 billion — a difference of roughly $14.4 billion, almost all of it public money, on that slice of the program alone.
“Find a gap that size in almost any other industry, and it would not read as a curiosity. It would read as a lead.”— Before the Counter
How the Rest of the World Solved This
The book then widens its lens beyond the United States. Visit London, Berlin, Paris, Toronto, or Tokyo, and the health systems, politics, and cultures differ sharply — yet each country arrives at strikingly similar, and far lower, prices for the same medicines. They did not copy one another; working independently, they discovered many of the same principles.
Before agreeing to pay for a new medicine, each of these systems asks a question American purchasing usually skips: does this drug provide enough added benefit to justify its price? The specific institutions vary: the United Kingdom's NICE evaluates cost-effectiveness before broad coverage; Germany lets a drug launch, then formally assesses its added benefit through IQWiG and G-BA; France grades added medical benefit on an explicit scale through HAS; Canada negotiates jointly across its provinces; Japan repeatedly reprices drugs after launch. Different institutions, different governments, remarkably similar results.
The numbers make the resulting gap concrete: a 2024 RAND analysis found U.S. brand-name drug prices running roughly 3.2 times those of comparison countries, even after accounting for rebates. Coleman states the honest counterpoint plainly — a buyer willing to say no will sometimes say no, and American patients often do get the newest medicines first, and that is a real trade-off, not an illusion. The country is not missing the idea, Coleman concludes — it has the idea working at home, inside the VA, and mirrored across every peer nation. What it lacks is the decision to extend it.
Who Pays for Tomorrow's Cures?
No argument in the drug-pricing debate carries more weight than this one, and the book gives it a full, serious hearing rather than dismissing it: high prices fund innovation, and cutting them means fewer future medicines. Coleman states the industry's case at its strongest before testing it.
What that argument does not answer, he notes, is how much reward is enough, or who should bear it. Much of the foundational science behind new drugs is paid for by American taxpayers through the National Institutes of Health. One widely cited analysis found NIH-funded research contributed to the science behind every one of 210 new drugs approved between 2010 and 2016, backed by more than $100 billion in NIH funding.
The book's most powerful test of the innovation argument is a natural experiment that has already run: if high prices were essential to innovation, countries that pay far less should have seen their access to new medicines dry up. They have not. When the nonpartisan Congressional Budget Office analyzed Medicare's new negotiation authority, it projected a modest effect on future drug development — on the order of roughly a dozen fewer drugs out of about 1,300 over thirty years, close to one percent — while industry-aligned analyses project substantially larger losses.
Why Isn't It Fixed?
If the mechanics are this well understood, and the VA already proves a fix is possible, the reasonable reader is entitled to ask why nothing has changed. The book's answer is structural rather than conspiratorial. Every proposed reform creates winners and losers, and the opposition to change is organized, well-funded, and permanent in a way patients' interests rarely are. Pharmaceutical and health-products lobbying totaled roughly $390 million in 2024, more than any other American industry in nearly every quarter since 2010.
Yet the country has tried, repeatedly, from both parties. President Trump's first-term Most Favored Nation order (2020) tried to borrow foreign reference prices directly, was challenged in court, and was rescinded. President Biden's Inflation Reduction Act (2022) built genuine domestic negotiating authority, projected by the CBO to save roughly $102 billion over ten years, but applied it to only a small, slowly growing list of drugs. And beginning in 2025, the Trump administration revived the Most Favored Nation concept through voluntary manufacturer agreements while launching TrumpRx, a government-hosted website where manufacturers post cash discount prices directly to consumers. Each approach, Coleman writes, addressed a different fraction of the problem, and none addressed the whole of it.
What Works
Rather than searching for one silver-bullet reform, the book's penultimate chapter assembles what the evidence already shows works, arguing that the country does not need to invent a new system — it needs to connect the disciplined one it already runs for veterans to the one it runs for everyone else. Six levers emerge from the preceding chapters: letting Medicare negotiate broadly by amending the 2003 clause; pairing independent value review with a national formulary; a durable ceiling tied to peer-country prices; cleaning up the supply chain by banning spread pricing and delinking PBM pay from list price; passing rebates through to patients at the counter; and restoring competition through patent reform and public-interest generic manufacturing, exemplified by the nonprofit Civica Rx, now producing more than seventy essential generic drugs.
The book closes not with a policy prescription but with a reckoning, laid out in an Author's Reflection titled "None Dare Call It Corruption." Coleman writes that he set out to investigate a pricing problem and instead uncovered something larger: a system in which every participant — manufacturers, PBMs, insurers, lobbyists, members of Congress — can honestly say they followed the law. Nothing in the story requires a secret meeting or a criminal conspiracy. That discovery forced him to stop asking who broke the law and start asking who wrote it.
Drug pricing, the book ultimately argues, is not the disease. It is the symptom easiest to see, because it is the one that shows up on a receipt in a patient's hand. Beneath it lies something larger and less visible — the system that finances American healthcare itself. That larger system, only glimpsed at the edges of Before the Counter, is the subject the trilogy turns to next, in Book Two: Behind the System.
The Final Finding
Watch the Epilogue
The book's closing argument, adapted for the screen — an eleven-minute walk through why every explanation for high drug prices is partly true, and why, together, they explain nothing.
"None Dare Call It Corruption" · 11 min · Robert Coleman, MS Pharm.